Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM

Actinium Pharmaceuticals

Actinium Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker ATNM. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Leukemia, Sickling Disorder Due

New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2000
Employees
58
Programs
8
Drugs
4
Patents
20
Clinical program

Iomab-B

Phase 3 · small molecule · Acute Myeloid Leukemia

Iomab-B for Acute Myeloid Leukemia is a Phase 3 program (small_molecule) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Actinium Pharmaceuticals projects Phase 3 small molecule active

Internal code Iomab-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Actinium Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Acute Myeloid Leukemia
Status
active
Trials
1

Clinical trials